BioXcel Therapeutics, Inc. Common Stock
Symbol: BTAI (NASDAQ)
2.28
▼ (-0.66%) -0.015
Company Description:
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Key Stats
- Today's Open: $2.25
- Today's High: $2.354
- Today's Low: $2.185
- Today's Volume: 602.55K
- Yesterday Close: $2.29
- Yesterday High: $2.395
- Yesterday Low: $2.28
- Yesterday Volume: 598.83K
- Last Min Volume: 165
- Last Min High: $2.275
- Last Min Low: $2.275
- Last Min VWAP: $2.275
Company Profile
- Name: BioXcel Therapeutics, Inc. Common Stock
- Website: https://www.bioxceltherapeutics.com
- Listed Date: 2018-03-08
- Location: NEW HAVEN, CT
- Market Status: Active
- CIK Number: 0001720893
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $44.99M
- Round Lot: 100
- Outstanding Shares: 19.65M
- Asset Type: CS
RECENT FILINGS FOR BTAI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-14 | 8-K | View |
| 2025-10-01 | 4 | View |
| 2025-10-01 | SCHEDULE 13G | View |
| 2025-09-16 | 4 | View |
| 2025-09-16 | 4 | View |
| 2025-09-16 | 4 | View |
| 2025-09-16 | 4 | View |
| 2025-09-15 | 8-K | View |
| 2025-09-10 | 8-K | View |
| 2025-09-02 | 4 | View |
| 2025-08-27 | 8-K | View |
| 2025-08-18 | 424B5 | View |
| 2025-08-18 | 8-K | View |
| 2025-08-18 | 8-K | View |
| 2025-08-15 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-11 | 8-K | View |
| 2025-08-11 | 8-K | View |
| 2025-08-06 | 8-K | View |
Latest News on BTAI